Comparative Pharmacology
Head-to-head clinical analysis: NEOSPORIN versus ZELSUVMI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEOSPORIN versus ZELSUVMI.
NEOSPORIN vs ZELSUVMI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Neosporin is a combination of three antibiotics: neomycin (aminoglycoside) inhibits bacterial protein synthesis by binding to 30S ribosomal subunit; polymyxin B (polymyxin) disrupts bacterial cell membrane integrity; bacitracin (polypeptide) inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier.
Nucleoside analog inhibitor of RNA-dependent RNA polymerase (NS5B polymerase) of hepatitis C virus, incorporating into viral RNA and causing chain termination.
Apply a thin layer topically to the affected area 1-3 times daily. May be covered with a sterile bandage.
ZELSUVMI (berotralstat) 150 mg orally once daily with food.
None Documented
None Documented
Variable based on severity of renal impairment. Normal renal function: 2-3 hours for neomycin (main component); polymyxin B: 4-6 hours. In anuria: half-life extends to 72-96 hours for neomycin.
Terminal elimination half-life is approximately 19.6 hours in healthy adults, supporting once-daily dosing.
Renal excretion accounts for >90% of elimination; primarily glomerular filtration with minimal tubular secretion. Small biliary/fecal elimination (<5%).
Primarily renal excretion as unchanged drug; approximately 60% recovered in urine and 20% in feces over 72 hours.
Category C
Category C
Topical Antibiotic
Topical Antibiotic